维生素D及其1α-羟基化衍生物所致高钙血症和高钙尿症的逆转率
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives.
作者信息
Kanis J A, Russell R G
出版信息
Br Med J. 1977 Jan 8;1(6053):78-81. doi: 10.1136/bmj.1.6053.78.
The rate of reversal of hypercalcaemia or hypercalciuria induced by calciferol, dihydrotachysterol, 1-alpha-hydroxycholecalciferol (1-alpha-OHD3), or 1-alpha, 25-dihydroxycholecalciferol (1-alpha, 25-(OH)2D3) was measured in three normal subjects, two patients with osteoporosis, and 14 patients with disorders resistant to vitamin D. The half time for reversal after stopping 1-alpha, 25 (OH)2D3 was less than that after stopping 1-alpha-OHD3, calciferol, or dihydrotachysterol. The differences observed were independent of the dose given or length of treatment. When 1-alpha-OHD3 or 1-alpha-25-(OH)2D3 was stopped patients with vitamin D resistant states (hypoparathyroidism, renal tubular hypophosphataemia, or chronic renal failure) showed less rapid reversal of hypercalcaemia and hypercalciuria than did normal subjects. These studies show one potential advantage of 1-alpha-25-(OH)2D3 over vitamin D, and possibly over 1-alpha-OHD3, in the management of vitamin D resistant states.
在三名正常受试者、两名骨质疏松症患者和十四名维生素D抵抗性疾病患者中，测定了由骨化醇、双氢速甾醇、1-α-羟胆钙化醇（1-α-OHD3）或1-α,25-二羟胆钙化醇（1-α,25-(OH)2D3）诱导的高钙血症或高钙尿症的逆转率。停止使用1-α,25-(OH)2D3后逆转的半衰期短于停止使用1-α-OHD3、骨化醇或双氢速甾醇后的半衰期。观察到的差异与给药剂量或治疗时长无关。当停止使用1-α-OHD3或1-α,25-(OH)2D3时，维生素D抵抗状态（甲状旁腺功能减退、肾小管性低磷血症或慢性肾衰竭）的患者与正常受试者相比，高钙血症和高钙尿症的逆转速度较慢。这些研究表明，在治疗维生素D抵抗状态方面，1-α,25-(OH)2D3相对于维生素D，可能也相对于1-α-OHD3，具有一个潜在优势。
Zotero 插件